Cell & Gene Therapy Trials: A Conversation with Adam Callahan (full interview)

Adam Callahan, Caidya’s Vice President of Clinical Development and Therapeutic Area Head for Hematology-Oncology, examines the distinct scientific and operational demands of cell and gene therapy trials. He explains differences between these therapeutic approaches, including patient identification, risk profiles, safety monitoring, and treatment logistics. The conversation also addresses specialized site selection, vendor coordination, personalized sponsor engagement, and the infrastructure required to manage complex sample processing and administration timelines. Adam also explores how electronic medical records, claims data, diagnostics, precision medicine, next-generation sequencing, artificial intelligence, and machine learning are refining patient identification and supporting more adaptable trial execution.